CRIS : Summary for Curis, Inc. - Yahoo Finance

U.S. Markets close in 30 mins.

Curis, Inc. (CRIS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.80-0.17 (-5.72%)
As of 3:29PM EST. Market open.
People also watch
ARQLCERSAGENCYTRARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.97
Open2.98
Bid2.78 x 1000
Ask2.79 x 1000
Day's Range2.78 - 3.06
52 Week Range1.25 - 3.72
Volume332,718
Avg. Volume604,724
Market Cap393.54M
Beta2.60
PE Ratio (TTM)-5.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Curis, Inc. – Value Analysis (NASDAQ:CRIS) : January 13, 2017
    Capital Cube4 days ago

    Curis, Inc. – Value Analysis (NASDAQ:CRIS) : January 13, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Curis, Inc. a score of 25. Our analysis is based on comparing Curis, Inc. with the following peers – Exelixis, Inc., Infinity Pharmaceuticals, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Tetralogic Pharmaceuticals Corporation, Celldex Therapeutics, Inc., Pfizer Inc., Celgene Corporation and Madrigal Pharmaceuticals, Inc. ... Read more (Read more...)

  • Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : January 12, 2017
    Capital Cube5 days ago

    Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : January 12, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Curis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • GlobeNewswire8 days ago

    Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

    LEXINGTON, Mass., Jan. 09, 2017-- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced ...